Smith Asset Management Group LP decreased its position in Hologic, Inc. (NASDAQ:HOLX) by 44.9% during the second quarter, Holdings Channel reports. The fund owned 683,903 shares of the medical equipment provider’s stock after selling 558,427 shares during the period. Smith Asset Management Group LP’s holdings in Hologic were worth $31,025,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in HOLX. Stratos Wealth Partners LTD. increased its position in shares of Hologic by 0.6% in the second quarter. Stratos Wealth Partners LTD. now owns 4,954 shares of the medical equipment provider’s stock worth $225,000 after buying an additional 30 shares during the last quarter. Cleararc Capital Inc. increased its position in shares of Hologic by 1.1% in the first quarter. Cleararc Capital Inc. now owns 6,843 shares of the medical equipment provider’s stock worth $291,000 after buying an additional 77 shares during the last quarter. Compton Capital Management Inc. RI increased its position in shares of Hologic by 0.6% in the first quarter. Compton Capital Management Inc. RI now owns 16,810 shares of the medical equipment provider’s stock worth $715,000 after buying an additional 100 shares during the last quarter. Advantus Capital Management Inc increased its position in shares of Hologic by 0.4% in the first quarter. Advantus Capital Management Inc now owns 27,936 shares of the medical equipment provider’s stock worth $1,189,000 after buying an additional 116 shares during the last quarter. Finally, Shell Asset Management Co. increased its position in shares of Hologic by 0.7% in the first quarter. Shell Asset Management Co. now owns 24,647 shares of the medical equipment provider’s stock worth $1,049,000 after buying an additional 182 shares during the last quarter. Hedge funds and other institutional investors own 94.46% of the company’s stock.

Shares of Hologic, Inc. (HOLX) opened at 37.39 on Friday. Hologic, Inc. has a 12-month low of $35.15 and a 12-month high of $46.80. The stock has a market cap of $10.49 billion, a P/E ratio of 13.93 and a beta of 0.90. The company has a 50 day moving average price of $43.97 and a 200 day moving average price of $42.90.

Hologic (NASDAQ:HOLX) last posted its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported $0.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.49 by $0.01. Hologic had a return on equity of 23.18% and a net margin of 25.65%. The business had revenue of $806.10 million for the quarter, compared to analysts’ expectations of $799.70 million. During the same quarter last year, the firm earned $0.51 earnings per share. The business’s revenue was up 12.4% on a year-over-year basis. Analysts anticipate that Hologic, Inc. will post $2.01 earnings per share for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this story can be read at https://www.watchlistnews.com/smith-asset-management-group-lp-has-31-03-million-stake-in-hologic-inc-nasdaqholx/1474704.html.

A number of equities analysts recently commented on the company. Stifel Nicolaus lifted their price objective on Hologic from $45.00 to $48.00 and gave the stock a “buy” rating in a research report on Thursday, May 11th. Jefferies Group LLC set a $49.00 price objective on Hologic and gave the stock a “buy” rating in a research report on Sunday, May 28th. Piper Jaffray Companies reiterated a “buy” rating and set a $51.00 price objective on shares of Hologic in a research report on Friday, July 14th. Bank of America Corporation reiterated a “neutral” rating and set a $48.00 price objective (up previously from $44.00) on shares of Hologic in a research report on Friday, July 21st. Finally, Barclays PLC reiterated an “overweight” rating and set a $53.00 price objective (up previously from $50.00) on shares of Hologic in a research report on Monday, July 17th. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the company’s stock. Hologic currently has an average rating of “Buy” and a consensus price target of $48.64.

In related news, Director Elaine Ullian sold 8,938 shares of the stock in a transaction on Friday, June 2nd. The stock was sold at an average price of $43.99, for a total value of $393,182.62. Following the transaction, the director now directly owns 23,810 shares of the company’s stock, valued at approximately $1,047,401.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Peter J. Valenti III sold 10,005 shares of the stock in a transaction on Tuesday, May 30th. The stock was sold at an average price of $43.44, for a total value of $434,617.20. Following the completion of the transaction, the insider now directly owns 20,994 shares in the company, valued at $911,979.36. The disclosure for this sale can be found here. Insiders have sold 60,627 shares of company stock worth $2,632,911 in the last 90 days. Insiders own 0.79% of the company’s stock.

Hologic Company Profile

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.